Kanabo Group PLC (LSE:KNB) has seen its share price climb on the back of a statement noting that the UK medical regulator’s plans for e-cigarettes to help people quit smoking.
The medical cannabis and research and development company put out a statement noting the UK’s Medicines and Healthcare Products Regulatory Agency had announced that the NHS “could soon prescribe e-cigarettes to help patients stop smoking tobacco products”.
This seemed to be based on guidance from the MHRA in October, where it detailed the steps required for e-cigs to be licensed as medicinal products.
The agency said products would need to meet the same standards expected of medicinal products, at which point clinicians would decide on a case-by-case basis whether it would be appropriate to prescribe an e-cigarette.
Dr June Raine, chief executive of the MHRA, said at the time that the updated guidance “is a strong first step towards availability of safe and effective licensed e-cigarette products”.
Kanabo shares were up 4.55% at time of publication, trading at 13p.
